TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS

Title:

TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS

Document Type and Number:

Japanese Patent JP2017048249

Kind Code:

A

Abstract:

PROBLEM TO BE SOLVED: To provide, as one thing, a compound suitable for use as a procoagulant.SOLUTION: The present invention provides a procoagulant fusion protein, a polynucleotide encoding the fusion protein, and cells expressing the fusion protein. The present invention also provides a fusion protein for use as a medicament. The fusions protein according to the present invention may treat individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors.SELECTED DRAWING: Figure 26

More Like This:

JP2022515258	Multispecific antigen-binding proteins capable of binding to CD19 and CD3, and their use
JP2015192672	METHOD OF EVALUATING ENDOTHELIAL CELL EXPRESSION PATTERNS
WO/1993/014125	NOVEL LYMPHOCYTIC ANTIGEN, CORRESPONDING ANTIBODY AND APPLICATIONS THEREOF

Inventors:

IDA HILDEN
LARS CHRISTIAN PETERSEN
JENS BREINHOLT
METTE DAHL ANDERSEN
JAIS ROSE BJELKE
THOMAS EGEBJERG

Application Number:

JP2016236487A

Publication Date:

March 09, 2017

Filing Date:

December 06, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

NOVO NORDISK AS

International Classes:

C07K16/28

Foreign References:

US20040180409A1	2004-09-16
US20080131423A1	2008-06-05

Attorney, Agent or Firm:

Yasuhiko Murayama
Shinya Mitsuhiro
Tatsuhiko Abe

Previous Patent: Cylindrical hepatitis C virus inhibitor containing fragmentation {2- [4- (biphenyl 4- Il ) -1H-imida...

Next Patent: A method and a constituent for sending a curative medicine